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Abstract
Background: Agent-based models are valuable for examining systems where large numbers of discrete individuals interact
with each other, or with some environment. Diabetic Veterans seeking eye care at a Veterans Administration hospital
represent one such cohort.
Objective: The objective of this study was to develop an agent-based template to be used as a model for a patient with
diabetic retinopathy (DR). This template may be replicated arbitrarily many times in order to generate a large cohort which
is representative of a real-world population, upon which in-silico experimentation may be conducted.
Methods: Agent-based template development was performed in java-based computer simulation suite AnyLogic
Professional 6.6. The model was informed by medical data abstracted from 535 patient records representing a retrospective
cohort of current patients of the VA St. Louis Healthcare System Eye clinic. Logistic regression was performed to determine
the predictors associated with advancing stages of DR. Predicted probabilities obtained from logistic regression were used
to generate the stage of DR in the simulated cohort.
Results: The simulated cohort of DR patients exhibited no significant deviation from the test population of real-world
patients in proportion of stage of DR, duration of diabetes mellitus (DM), or the other abstracted predictors. Simulated
patients after 10 years were significantly more likely to exhibit proliferative DR (P,0.001).
Conclusions: Agent-based modeling is an emerging platform, capable of simulating large cohorts of individuals based on
manageable data abstraction efforts. The modeling method described may be useful in simulating many different
conditions where course of disease is described in categorical stages.
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Introduction
VA St. Louis Healthcare System
The Veterans Administration (VA) St. Louis Healthcare System
is a tertiary care facility with 218 medical and surgical beds,
serving more than 55,000 Veterans in eastern Missouri and
southern Illinois. The eye clinic is staffed by three attending, two
resident and two student optometrists, as well as 3.8 full time-
equivalent ophthalmologists. The clinic sees approximately 14,000
unique patients annually, including 955 patients with a primary
diagnosis of diabetic retinopathy as of 2011. Current VA policy is
that all diabetic patients receive a diabetic eye exam at least once
every year. This suggests that some 3,500 diabetic eye exams will
need to be performed annually, given that the rate of diabetes in
the Veteran population is more than 25% [1].
Diabetic Retinopathy
Diabetes is epidemic in the United States and growing, with
nearly 1 in 10 adults over the age of 45 suffering from the disease
[2]. According to Miller et al., annual expenditures on diabetes
treatment and care are nearly $100 billion, and consume nearly
15% of all health care outlays. In the Veteran population, diabetes
is far more prevalent than the population as a whole, even
restricted to adults, with greater than 25% of Veterans suffering
[1]. Of the population of adults with diabetes, 28.5% suffer from
diabetic retinopathy (DR), and 4.4% from vision threatening DR,
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costing over $500 million dollars annually [3]. DR is the leading
cause of new blindness in adults 20–74 [4].
Agent-based Modeling
Agent-based models (ABM) are formulated around the creation
of a cohort of objects, known as ‘‘agents’’, which are placed in an
environment and imbued with individuated attributes and rules for
interaction with the environment and with other agents. These
agents represent individual members of a larger group. They may
be seen as individuals within a population, or as cells in an
organism. Use of computer simulation for the study of complex
systems employing agents is a relatively new endeavor, emerging
during the mid 1990’s [5]. These systems are characterized as
consisting of interactive autonomous agents, the environment they
inhabit, and by exhibiting - in the words of Forrest and Jones -
‘‘[u]nanticipated global properties’’. (This is generally referred to
today as ‘‘emergent behavior’’.) As dynamic models, agent-based
models evolve over time, and are designed to simulate real-world
complex systems which do the same. ABMs allow us to examine
population level effects of diffusion of information and adoption of
behaviors [6].
ABM is being used effectively in a number of capacities in
medical research. The early uses of ABM in medicine were at the
level of biological systems, for example modeling inflammatory
response [7], granuloma formation in tuberculosis [8], and
immune response [9]. More recently, the potential for ABM to
provide relevant and enlightening results in the field of epidemi-
ology has begun to be realized. The capacity for agents to
represent human individuals, imbued with a demography repre-
sentative of a real-world population opens the potential for in-silico
epidemiological studies [10]. ABM also has demonstrated appli-
cation to the field of human behavior study [11–12], and in more
traditional settings of scheduling in medical environments [13].
Additionally, ABM has been shown to provide value in predicting
ophthalmic outcomes as well, particularly in the field of age-
related macular degeneration [14–15].
Objective
This paper describes the development of a template for a
diabetic agent, in the context of an agent-based model of a cohort
of patients with or at risk for DR. Our goal is to describe the
process of the creation of an agent, the process of informing that
agent with data abstracted from medical records, and the
replication of a simulated cohort of identical size to the
retrospective, real-world cohort. We additionally present the
methodology for validating the simulated cohort against real-
world test data. Finally, we allow the cohort to age ten simulated
years, and report the outcomes.
Methods
Cohort Selection and Data Abstraction
The population of real-world patients constituting the cohort for
this study will be those patients who have sought surveillance or
treatment for DR at the VA St. Louis Healthcare System eye clinic
during the period from CY 2006–2010. We restrict to those
patients determined to be definitely diabetic, as defined by the
ProClarity Diabetes Cube: either one inpatient or two outpatient
diagnoses, or a prescription for a greater than 30 day supply of
diabetes specific pharmaceuticals. We further restrict to those
patients with a primary diagnosis of one of four ICD9 codes for
ophthalmic complications: 362.0 for proliferative, non-prolifera-
tive, and background diabetic retinopathy or 362.10 background
retinopathy unspecified, 379.23 vitreous hemorrhage, and 250.5
diabetes mellitus with ophthalmic manifestation. This allows us to
identify only those patients exhibiting non-proliferative diabetic
retinopathy (NPDR), and proliferative diabetic retinopathy (PDR).
This resulted in 535 records patient records. Elements
abstracted included patient age, gender, BMI, current HbA1c
(glycated hemoglobin); dichotomous variables included hyperten-
sion, dyslipidemia, diabetic nephropathy, and current tobacco use.
Finally, current state of DR (mild, moderate or severe NPDR, or
PDR) was abstracted. Of the identified records, duration of
diabetes could not be determined in 34 patients, and the records
were excluded. Finally, the remaining set of 501 records was
randomly divided into the training (n = 351) and test (n = 150) data
sets. The sample sizes were chosen to have as large a training set as
possible while maintaining.90% statistical power to detect a 10%
variation in the continuously distributed predictors in the test data
set. This protocol was reviewed and approved by the VA St. Louis
Healthcare System Institutional Review Board, and a Waiver of
Informed Consent was granted for collection of existing data.
The Statechart Model
The Agent template was designed using AnyLogic Professional
6.6, a Java-based simulation suite capable of multiple types of
simulation modeling. The fundamental structure used to model
the progression of DR within the agent is the ‘statechart’. At the
most basic conceptual level, a statechart is simply a discretized
condition, and rules for how that condition changes. In practice, a
statechart is a graphically represented collection of ‘states’,
conditions which an agent may inhabit, and ‘transitions’, rules
for how an agent exits one state and enters another. Statecharts
are easily represented as directed graphs, as the statechart for DR
shown in figure 1, where states are nodes on the graph (generally
enlarged for clarity), and transitions are edges, with arrowheads
showing their direction of action.
Figure 1. Statechart model for Diabetic Retinopathy. DR:
Diabetic Retinopathy NPDR: Non-proliferative Diabetic Retinopathy
PDR: Proliferative Diabetic Retinopathy PRP: Pan-retinal Photocoagula-
tion.
doi:10.1371/journal.pone.0066812.g001
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The statechart consists of five possible states: (1) no retinopathy,
(2) non-proliferative diabetic retinopathy (NPDR), (3) proliferative
diabetic retinopathy (PDR), (4)legal vision loss (VL), and (5) a final
state called ‘death’. Because the agent model was developed to be
used to simulate the course of disease in a dynamic population
over the course of many years, agent capacity to exit the cohort
was included in the model. Agent death is modeled according to
life tables published by the Social Security Statistical Tables
website (www.ssa.gov/OACT/STATS/). The initial population of
agents is designed to mimic the population of Veterans at VA St.
Louis Healthcare System who already carry a diagnosis of DR in
some form. Therefore, for validation purposes, we defined the
state ‘‘no retinopathy’’ to be uninhabited at model initiation.
However when new agents enter the cohort during the simulation
run, they are initially assigned to inhabit state (1) with p= 0.715
[3].
Additional Fields Associated with the Agent
In addition to the statechart, each agent is imbued with several
data structures necessary to simulate the progression of DR. First,
there are variables, or fields, describing the demography and
health status of the agent. These are age, gender, duration of
diabetes, BMI, recent HbA1c, and four dichotomous variables
indicating presence or absence of hypertension, dyslipidemia,
diabetic nephropathy, and current tobacco use. These represent
the predictors a priori hypothesized to be associated with the
progression of DR, or necessary to thoroughly characterize the
population simulated. Distribution of values for these fields for the
training and test data sets may be seen in table 1. The abstracted
data were fit to probability density functions using Stat::Fit
Version 2 (Geer Mountain Software Corporation, South Kent,
Connecticut), which were called to inform the individual agents
upon initiation of the simulated cohort.
The final data structure included as part of the agent is a
subroutine of computer code called an ‘event’. This event
functions as an annual update for the agent, describing the
change in the predictors from year to year. The event increases
both age and duration of DM by one, and determines whether
initial onset of DR, or initial onset of vision loss, occurred during
the past year.
Calculating Probability of DR Progression
The multivariate logistic regression model provides a function,
which may be expressed as a probability in the form:
P(Advancement)~
e(b
Xzm)
1ze(b
Xzm)
where b and m represent the coefficient vector and intercept,
respectively, from the logistical regression, and X represents the
vector of values of the predictors themselves. The annual ‘event’
generates these probabilities based on the agent’s own unique
predictors, and then generates a uniformly distributed random
number on [0,1] to test if the probability of advancement is
satisfied during that year. If appropriate, the agent updates its
individualized state-chart, transitioning from NPDR to PDR.
There are four other types of transitions: the first is the
transition from ‘no-retinopathy’ (state 1) to ‘NPDR’ (state 2).
Because the real-world cohort was restricted to patients already
exhibiting DR, the expected time from diagnosis of DM to onset of
mild non-proliferative retinopathy was determined from local
administrative data, showing a 7.7% annual incidence. This is in
line with estimates from the literature, with various reports
showing incidence rates of 8.0%–8.4% in recent Australian
populations [16], 3.9%–7.1% in a population of Medicaid patients
from the 1990s [17]. The second is for transition from proliferative
retinopathy (state 3) to vision loss (state 4)for which rates were
taken to be 0.7%, annualized from published incidences [18]. The
probability of transition from any state to the state ‘death’ (state 5)
is computed by accessing the life table described above, using the
agent’s age as an input. Lastly, agents are allowed to transition
from PDR back to NPDR through the application of pan-retinal
Table 1. Training, Test, and Simulated Data.
Training Data Test Data Simulated Data Test Type P value
N 351 150 501 Test data to Simulated data
Age -yr 67.569.4 67.368.9 66.668.7 t test 0.382
Gender- male 345 (98.3) 148 (98.7) 494 (98.6) x square 0.476
Duration of DM - yr 21.569.0 20.568.6 21.168.8 t test 0.451
BMI 32.266.3 32.366.8 31.966.6 t test 0.537
A1c 8.261.8 8.061.5 8.261.7 t test 0.359
Hypertension 344 (98.0) 149 (99.3) 488 (97.4) x square 0.153
Dyslipidemia 297 (84.3) 137 (92) 439 (87.6) x square 0.139
Diabetic Nephropathy 124 (35.3) 51 (34) 186 (37.1) x square 0.485
Current Tobbaco User 88 (25.1) 25 (16.7) 110 (21.9) x square 0.161
NPDR 258 (73.5) 121 (80.7) 369 (73.6) x square 0.081
PDR 93 (26.5) 29 (19.3) 132 (26.4)
DM – Diabetes Mellitus.
NPDR - non proliferative diabetic retinopathy.
PDR - proliferative diabetic retinopathy.
BMI - body mass index.
A1c =Hemoglobin A1c.
Values reported as average 6 standard deviation, or number (percent).
P value represents comparison of Test Data to Simulated Data.
doi:10.1371/journal.pone.0066812.t001
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photocoagulation, which may be scheduled after the transition
from NPDR to PDR.
Results
Predictors Associated with DR Progression
Odds ratios were computed using SAS software (SAS 9.2, Cary,
NC, USA). Three of the abstracted predictors were found to have
statistically significant associations with DR progression: duration
of DM (OR 1.059, 95% CI 1.033–1.086), presence of diabetic
nephropathy (OR 2.163, 95% CI 1.398–3.346), and BMI (OR
0.961, 95% CI 0.927–0.996). The counterintuitive role of BMI
may be due to the truncated nature of the data, which included
very few normal- or under-weight individuals. Age, gender,
hypertension, dyslipidemia, current tobacco use, and recent
HbA1c were all found to lack statistical significance with regard
to stage of DR in our cohort.
Validation of Simulated Cohort against a Real-World Test
Cohort
We generated a simulated cohort of 501 individuals, in order to
replicate the real-world cohort size. The initial simulated cohort
did not show any significant variation from the test cohort in any
measured value. Student’s t-tests were used for age, duration of
DM, BMI, and HbA1c. x2 tests were used for the dichotomous
values of hypertension, dyslipidemia, diabetic nephropathy,
tobacco use, and initial stage of DR, either NPDR or PDR. As
is necessary for all simulation validation, the ‘test’ data set were not
used in training the simulation or generating distributions of
predictors. Therefore, comparing the simulated cohort to the test
cohort demonstrates that we are capable of generating a
population of agents which accurately characterizes the population
of Veterans served by VA St. Louis Healthcare System, rather
than duplicating a specific subset of those individuals. Complete
distributions, specific statistical tests, and p-values are shown in
table 1. It is important to note that in contrast to most commonly
reported p-values, for purposes of cohort validation, we desire
non-significance (i.e., p.0.05); that is, we seek to show that there is
no statistically significant difference between the two populations
in the tested parameter.
Demographics of Simulated Cohort after 10 Simulated
Years
The model was then run forward in time 10 years, and the
population examined again. Of the 501 agents beginning the
simulation, 327 survived to its termination. The agents which
entered state 5 (death) during the simulation were older, (78.1 vs.
74.9, p,0.0001), but had shorter duration of DM (26.4 vs. 30.4,
p,0.0001). This is as we would expect: agents beginning the
simulation with a lesser age were less likely to die during the ten
year period. Thus, they had more time to accrue years of duration
of their diabetes. Surviving patients were overwhelmingly in DR
state 2, PDR, with 244 inhabiting this state, 78 with NPDR, and 5
with vision loss. Patients not surviving to the end of the simulation
were more evenly split, with 98 cases of NPDR, and 76 cases of
PDR (p,0.0001). A sample agent’s probability of advancement,
prepared separately, is shown in Figure 2. When initialized
without DR, the agent has a 7.7% probability of developing
incident BDR. After 3 years, BDR develops, and the probability of
developing PDR is based on the multivariate regression described
above. After year 7 the agent develops PDR, and the transition
probability drops to 0.7% annual incidence of vision loss. The
sample agent shown does not develop VL during the ten-year
simulation period, and does not die during the ten-year simulated
period.
Discussion
Health services research, in the VA and elsewhere, is
increasingly focused on implementation science and policy
research. As we consider the extraordinary demand the health
care system is expected to confront over the coming decades, we
must develop tools that will allow us to identify those interventions
and policies most likely to have large positive effects on our ability
to provide care for a growing and aging population. Good health
care policy must first be informed by what it is possible to achieve.
Determining the maximum effect sizes of various interventions
and policies, in terms of their ability to influence access to care or
patient outcomes, will be critical in determining the overall value
of potential policies. The development of tools which can rate
potential interventions according to their likely impact on patient
outcomes and access will provide important evidence either
recommending or discouraging adoption, where previously such
evidence was subject to large error as a result of speculation.
Agent-based modeling is exactly one such tool. The develop-
ment of simulated cohorts of agents, which mimic real-world
populations of patients, allows us to test in-silico interventions
which previously could not be tested at all prior to adoption, or
which would be prohibitively expensive or harmful in trials should
they turn out to be ineffective. While the state of the art of agent-
based models is insufficient to, for example, replace real-world
clinical trials, the current work shows that they are capable of
simulating very realistic cohorts of patients. These cohorts may
then be examined under various test conditions, with population-
level outcomes used as hypothesis testing criteria.
The development of the simulated cohort essentially creates a
sandbox, in which various policy, capacity, and implementation
concepts may be tested for efficacy and efficiency. Having this
cohort available for such purposes is beneficial in at least three
ways. First, we are able to test ideas without making large sunk-
cost investments with uncertain outcomes. Second, we are able to
experiment with a realistic population while shielding patients
from any risk associated with planned interventions. Third, by
allowing us to determine the likely limits of an intervention’s effect
size, agent-based models show potential for the development of
evidence-based performance measures. Evidence-based perfor-
mance measures will allow us to take into account not only the
patient population and best-practices recommendations for care,
but also the systems-level evidence of what the delivery apparatus,
that is, the clinical and hospital systems, can provide.
These models may also be employed in health economics
research. Because they allow us to generate cost functions at the
individual patient level, we can calculate expected costs of various
policies, interventions, and implementations in response to
complex scenarios. Their sensitivity is greater than large scale
probabilistic models, as they can predict interactions among the
agents (and, if modeled, their environment), which may be
unpredictable prior to experimentation. Finally, the ability to
create sophisticated virtual patients may be of use in informing
power calculations for real-world RCTs. Because the number of
agents may be arbitrarily controlled, it would be possible to run
several simulated RCTs using the best-available patient models, in
order to assure that the statistical power of a planned RCT will be
sufficient to detect likely results. Similarly, because effect-sizes of
treatment may be subjected to sensitivity analysis, agent-based
simulations may be useful in determining the power needed to
detect the minimal effect size in a realistic simulated population.
Agent Based Modeling for Diabetic Retinopathy
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Limitations, Future Work, and Conclusions
Limitations
The real-world retrospective cohort for this model is relatively
small, representing only 535 patients. We believe that with a larger
sample size, a greater number of statistically significant predictors
could be found. Additionally, while the recent HbA1c of the
patients was not found to be a significant predictor of DR state, we
believe that a longer term measure will significantly inform the
model, based on known relationships between HbA1c and DR
progression [19]. The seemingly protective action of BMI on the
multiple regression model is possibly due to the fact that our data is
truncated on the low end; that is, our sample includes very few
patients of normal weight, or underweight. However, it is also
possible that our population is not well measured by BMI in terms
of adiposity compared with lean muscle mass. Because this effect
was an artifact found in the real-world data, it would be present in
any predictive model based on the same real-world cohort.
We were not able to find statistically significant predictive value
for the various stages of NPDR (mild, moderate, severe), a result
we believe to be due to the small sample size and ‘snapshot’ nature
of the data abstraction. Therefore, for the purposes of this pilot
study, it was decided to restrict prediction of DR progression to
NPDR versus PDR, for which we have good significance
indicators. We feel this is an appropriate restriction for two
reasons. First, our primary aim is to develop a cohort which will
allow us to predict the demand for pan-retinal photocoagulation, a
laser treatment for DR which is indicated for PDR, but ordinarily
not indicated for NPDR [20]. Second, it is common practice in the
literature to distinguish at the level of NPDR v PDR [3].
Future Work
The next phase of this project is to test the consequences of
annual vs. bi-annual (and longer) retinopathy screening proce-
dures. In this way we will determine the influence of mean
screening interval on the rate of incident vision loss in the
population. This work will involve allowing the agents to interact
by competing for resources at a simulated ophthalmology clinic.
This represents an application of agent-based modeling to the
generation of evidence-based performance measure, in a circum-
stance where real-world experimentation cannot be responsibly
conducted, should bi-annual or longer screening turn out to have
serious consequences for patient vision. Our goal is to provide a
recommendation for the appropriate screening interval to
maximize access to care for all patients while preserving sighted
life-years.
Conclusions
Agent-based modeling provides a platform for the development
of sophisticated simulated cohort models. These models may
provide valuable insight for implementation science, translational
medicine, and health economic models. Specifically, the use of
agent-based modeling to examine the population of diabetic
Veterans seeking care at a regional VA Medical Center shows
potential for aiding in evidence-based policy and performance
measure.
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